Campath , Mabcampath(alemtuzumab)
Campath, Lemtrada (alemtuzumab) is an antibody pharmaceutical. Alemtuzumab was first approved as Campath on 2001-05-07. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat b-cell chronic lymphocytic leukemia and multiple sclerosis. The pharmaceutical is active against CAMPATH-1 antigen.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Campath (discontinued: Campath)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| b-cell chronic lymphocytic leukemia | — | D015451 | C91.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
alemtuzumab, Campath , Genzyme Corporation | |||
| 2108-05-07 | Orphan excl. | ||
alemtuzumab, Lemtrada, Genzyme Corporation | |||
| 2108-05-07 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0202 | Injection, alemtuzumab, 1 mg |
Clinical
Clinical Trials
387 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 4 | 5 | 8 | 7 | 23 | 45 |
| Sclerosis | D012598 | — | — | 5 | 6 | 8 | 6 | 19 | 42 |
| Kidney transplantation | D016030 | — | — | 4 | 9 | 2 | 8 | 5 | 25 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 2 | 5 | 5 | 4 | 16 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 3 | 3 | — | 3 | 1 | 8 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 3 | 4 | — | 1 | 2 | 7 |
| Graft rejection | D006084 | — | — | 1 | 2 | — | 2 | 3 | 7 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 2 | 3 | — | 2 | 1 | 6 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 3 | 2 | — | 1 | — | 4 |
| Vasculitis | D014657 | HP_0002633 | — | 1 | — | — | 1 | — | 2 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 34 | 91 | 6 | — | 10 | 115 |
| Lymphoma | D008223 | — | C85.9 | 26 | 55 | 2 | — | 6 | 74 |
| Lymphoid leukemia | D007945 | — | C91 | 16 | 53 | 2 | — | 7 | 66 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 10 | 46 | 3 | — | 7 | 60 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 16 | 28 | 2 | — | 4 | 38 |
| Myelodysplastic syndromes | D009190 | — | D46 | 9 | 30 | 3 | — | — | 32 |
| Syndrome | D013577 | — | — | 8 | 25 | 2 | — | 2 | 30 |
| Preleukemia | D011289 | — | — | 10 | 26 | 2 | — | — | 29 |
| Anemia | D000740 | HP_0001903 | D64.9 | 8 | 17 | 1 | — | 4 | 23 |
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 3 | 16 | 1 | — | 4 | 21 |
Show 36 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 11 | 22 | — | — | 1 | 25 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 11 | 14 | — | — | 3 | 21 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 7 | 15 | — | — | 1 | 18 |
| Neoplasms | D009369 | — | C80 | 5 | 12 | — | — | 1 | 16 |
| Hodgkin disease | D006689 | — | C81 | 3 | 14 | — | — | 1 | 15 |
| Hematologic neoplasms | D019337 | — | — | 6 | 9 | — | — | 1 | 12 |
| Plasma cell neoplasms | D054219 | — | — | 6 | 8 | — | — | 1 | 10 |
| Primary immunodeficiency diseases | D000081207 | — | — | 2 | 8 | — | — | 2 | 10 |
| B-cell lymphoma | D016393 | — | — | 4 | 7 | — | — | 1 | 10 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 3 | 8 | — | — | 1 | 9 |
Show 158 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lysosomal storage diseases | D016464 | — | — | 1 | — | — | — | 1 | 2 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | 2 | — | — | — | — | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
| Digestive system neoplasms | D004067 | — | — | 1 | — | — | — | — | 1 |
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
| Rhabdoid tumor | D018335 | — | — | 1 | — | — | — | — | 1 |
| Clear cell adenocarcinoma | D018262 | — | — | 1 | — | — | — | — | 1 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | — | — | — | — | 1 |
| Rhabdomyosarcoma | D012208 | — | — | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 hyper-igm immunodeficiency syndrome | D053307 | — | — | — | — | — | — | 1 | 1 |
| Polyomavirus infections | D027601 | EFO_0007451 | — | — | — | — | — | 1 | 1 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | — | 1 | 1 |
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | — | — | — | — | 1 | 1 |
| Viremia | D014766 | — | B34.9 | — | — | — | — | 1 | 1 |
| Thrombasthenia | D013915 | — | D69.1 | — | — | — | — | 1 | 1 |
| Bronchiolitis obliterans syndrome | D000092122 | — | — | — | — | — | — | 1 | 1 |
| Hemoglobin sc disease | D006450 | EFO_1001797 | D57.2 | — | — | — | — | 1 | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alemtuzumab |
| INN | alemtuzumab |
| Description | Immunoglobulin G 1 (human-rat monodonal CAMPATH-1H 71-chain anti-human antigen CD52), disulfide with human-rat monoclonal CAMPATH-1H light chain, dimer |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >1CE1:H|PROTEIN (CAMPATH-1H:HEAVY CHAIN)
QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQ
FSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE
>1CE1:L|PROTEIN (CAMPATH-1H:LIGHT CHAIN)
DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQP
EDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR |
Identifiers
| PDB | 1BEY, 1BFO, 1CE1, 6OBD |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201587 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00087 |
| UNII ID | 3A189DH42V (ChemIDplus, GSRS) |
Target
Agency Approved
CD52
CD52
Organism
Homo sapiens
Gene name
CD52
Gene synonyms
CDW52, HE5
NCBI Gene ID
Protein name
CAMPATH-1 antigen
Protein synonyms
Cambridge pathology 1 antigen, CD52, CD52 antigen (CAMPATH-1 antigen), CDw52, CDW52 antigen (CAMPATH-1 antigen), Epididymal secretory protein E5, epididymis secretory sperm binding protein Li 171mP, He5, HEL-S-171mP, Human epididymis-specific protein 5
Uniprot ID
Mouse ortholog
Cd52 (23833)
CAMPATH-1 antigen (Q64389)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,503 documents
View more details
Safety
Black-box Warning
Black-box warning for: Campath, Lemtrada
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18,334 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use